SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
LOE ApproachingNDAORALTABLET
Approved
May 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH by Fosun Pharma is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1982.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfamethoxazole and trimethoprim (SMX-TMP) is a fixed-dose combination antibiotic that inhibits bacterial nucleic acid and protein synthesis through sequential blockade of folate metabolism. It is used to treat urinary tract infections, Pneumocystis jiroveci pneumonia, traveler's diarrhea, and other bacterial and protozoal infections. The synergistic mechanism reduces resistance development compared to monotherapy.
LOE Approaching
As a mature generic product approaching loss of exclusivity, the brand team is likely small and focused on operational efficiency and risk mitigation rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. The metabolism of…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.